Sysmex Inostics have signed an exclusive distributor agreement with IndivuTest, and its parent company Indivumed, a cancer research company focused on the development of individualized cancer diagnostics and therapies. This collaboration will offer Sysmex’s OncoBEAM services throughout Germany, Austria and Switzerland.
IndivuTest will be responsible for commercial and sample logistics, with all testing being performed in the Sysmex Inostics’ CLIA laboratory in Baltimore, Maryland.
Sysmex Inostics’ highly sensitive OncoBEAM services allow for molecular genetic analysis of cell-free tumor DNA from blood or plasma, delivering an individualized approach to complement treatment decision-making in oncology. OncoBEAM, a non-invasive platform, reveals new possibilities for cancer management, while minimizing costs and risks inherent with tissue biopsies. The OncoBEAM assays target a wide variety of clinically actionable genetic mutations in various cancers like melanoma, colorectal, breast and lung cancer, delivering information in real-time to support therapy selection, detection of emergent mutations and assessment of drug response.
Vishal Sikri, Vice President of Commercial Operations at Sysmex Inostics, stated: “IndivuTest is an ideal partner to introduce the full range of our CLIA-certified laboratory service portfolio to German, Austrian and Swiss oncologists and pathologists and we are proud to provide our customers with such a high level of service and local support.“
Hartmut Juhl, President and Chief Executive Officer of IndivuTest, as well as its parent company Indivumed stated that “this most recent collaboration with Sysmex Inostics is a tremendous opportunity for our companies to continue our long standing partnership, bringing targeted diagnostics and therapies to the bedside of cancer patients.” Juhl went on to point out that Sysmex is a trusted partner of the Indivumed Group of companies, having successfully acquired Inostics from Indivumed in 2013.
“Our companies share a vision to help every cancer patient attack their disease in the most effective and targeted manner possible” said Juhl.